Chimeric Antigen Receptor (CAR) T-Cell Products for Pediatric Cancers: Why Alternative Development Paths Are Needed

International BFM Study Group (I-BFM); Innovative Therapies for Children with Cancer (ITCC), and the European Society for Paediatric Oncology (SIOPE)

doi:10.1200/JCO.23.01314

Chimeric Antigen Receptor (CAR) T-Cell Products for Pediatric Cancers: Why Alternative Development Paths Are Needed

International BFM Study Group (I-BFM), Innovative Therapies for Children with Cancer (ITCC), and the European Society for Paediatric Oncology (SIOPE)

Pediatrics

Research output: Contribution to journal › Comment/debate

10 Scopus citations

Original language	English
Pages (from-to)	253-257
Number of pages	5
Journal	Journal of Clinical Oncology
Volume	42
Issue number	3
DOIs	https://doi.org/10.1200/JCO.23.01314
State	Published - 20 Jan 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1200/JCO.23.01314

Cite this

@article{b5564809ac3a4e64a42a2f79ab4e4b81,

title = "Chimeric Antigen Receptor (CAR) T-Cell Products for Pediatric Cancers: Why Alternative Development Paths Are Needed",

author = "{International BFM Study Group (I-BFM)} and {Innovative Therapies for Children with Cancer (ITCC), and the European Society for Paediatric Oncology (SIOPE)} and Claudia Rossig and Pearson, {Andrew D.} and Gilles Vassal and Nicole Scobie and Nick Bird and Patricia Blanc and Vormoor, {H. Josef} and Calkoen, {Friso G.} and Franco Locatelli and {del Bufalo}, Francesca and Susana Rives and Elad Jacoby and Adriana Balduzzi and Bourquin, {Jean Pierre} and Andr{\'e} Baruchel",

year = "2024",

month = jan,

day = "20",

doi = "10.1200/JCO.23.01314",

language = "אנגלית",

volume = "42",

pages = "253--257",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

International BFM Study Group (I-BFM) & Innovative Therapies for Children with Cancer (ITCC), and the European Society for Paediatric Oncology (SIOPE) 2024, 'Chimeric Antigen Receptor (CAR) T-Cell Products for Pediatric Cancers: Why Alternative Development Paths Are Needed', Journal of Clinical Oncology, vol. 42, no. 3, pp. 253-257. https://doi.org/10.1200/JCO.23.01314

Chimeric Antigen Receptor (CAR) T-Cell Products for Pediatric Cancers: Why Alternative Development Paths Are Needed. / International BFM Study Group (I-BFM); Innovative Therapies for Children with Cancer (ITCC), and the European Society for Paediatric Oncology (SIOPE).
In: Journal of Clinical Oncology, Vol. 42, No. 3, 20.01.2024, p. 253-257.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Chimeric Antigen Receptor (CAR) T-Cell Products for Pediatric Cancers

T2 - Why Alternative Development Paths Are Needed

AU - International BFM Study Group (I-BFM)

AU - Innovative Therapies for Children with Cancer (ITCC), and the European Society for Paediatric Oncology (SIOPE)

AU - Rossig, Claudia

AU - Pearson, Andrew D.

AU - Vassal, Gilles

AU - Scobie, Nicole

AU - Bird, Nick

AU - Blanc, Patricia

AU - Vormoor, H. Josef

AU - Calkoen, Friso G.

AU - Locatelli, Franco

AU - del Bufalo, Francesca

AU - Rives, Susana

AU - Jacoby, Elad

AU - Balduzzi, Adriana

AU - Bourquin, Jean Pierre

AU - Baruchel, André

PY - 2024/1/20

Y1 - 2024/1/20

UR - http://www.scopus.com/inward/record.url?scp=85182955084&partnerID=8YFLogxK

U2 - 10.1200/JCO.23.01314

DO - 10.1200/JCO.23.01314

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.comment???

C2 - 38011605

AN - SCOPUS:85182955084

SN - 0732-183X

VL - 42

SP - 253

EP - 257

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 3

ER -

Chimeric Antigen Receptor (CAR) T-Cell Products for Pediatric Cancers: Why Alternative Development Paths Are Needed

UN SDGs

Access to Document

Other files and links

Cite this